Blood Pressure Clinical Trial
Official title:
The Effects of Magnesium Salts on Vascular Stiffness: A Randomized Controlled Trial in Healthy Overweight and Slightly Obese Men and Women
This four-arm randomized controlled trial was designed to study the effects of magnesium supplements (total daily dose: 450 mg elemental magnesium) on vascular stiffness in healthy overweight and slightly obese men and women. In addition, the effects of magnesium supplements on blood pressure and gut microbiota will be evaluated. Three groups will receive magnesium supplements (magnesium oxide, magnesium citrate or magnesium sulphate) and one group will receive a placebo.
Status | Recruiting |
Enrollment | 162 |
Est. completion date | January 2020 |
Est. primary completion date | January 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 45 Years to 75 Years |
Eligibility |
Inclusion Criteria: - Aged between 45-70 years - Women postmenopausal: two or more years after last menstruation - BMI between 25-35 kg/m2 (overweight and slightly obese) - Plasma glucose < 7.0 mmol/L - Serum total cholesterol < 8.0 mmol/L (further testing is recommended for excessive hyperlipidemia (serum total cholesterol = 8.0 mmol/L) according to the Standard for cardiovascular risk management of the Dutch general practitioners community (NHG)) - Serum triacylglycerol < 4.5 mmol/L (Friedewald formula) - No current smoker - No diabetic patients - No familial hypercholesterolemia - No abuse of drugs - Less than 21 alcoholic consumptions per week - Stable body weight (weight gain or loss <3 kg in the past three months) - No use of proton pump inhibitors - No use of magnesium supplements - No severe medical conditions that might interfere with the study, such as epilepsy, asthma, kidney failure or renal insufficiency, chronic obstructive pulmonary disease, inflammatory bowel diseases, auto inflammatory diseases and rheumatoid arthritis - No active cardiovascular disease like congestive heart failure or cardiovascular event, such as an acute myocardial infarction or cerebro vascular accident - Willingness to give up being a blood donor (or having donated blood) from 8 weeks before the start of the study and during the study - No difficult venipuncture as evidenced during the screening visit - Written informed consent Exclusion Criteria: - High habitual dietary magnesium intake (defined as urinary magnesium excretion of 7.0 or 5.9 mmol/24-h or more for men and women, respectively) - Plasma glucose = 7.0 mmol/L - Serum total cholesterol = 8.0 mmol/L - Serum triacylglycerol = 4.5 mmol/L - Current smoker, or smoking cessation <12 months - Diabetic patients - Familial hypercholesterolemia - Abuse of drugs - More than 21 alcoholic consumptions per week - Unstable body weight (weight gain or loss > 3 kg in the past three months) - Use of proton pump inhibitors - Use of magnesium supplements - Severe medical conditions that might interfere with the study, such as epilepsy, asthma, kidney failure or renal insufficiency, chronic obstructive pulmonary disease, inflammatory bowel diseases, auto inflammatory diseases and rheumatoid arthritis - Active cardiovascular disease like congestive heart failure or cardiovascular event, such as an acute myocardial infarction or cerebro vascular accident - Not willing to give up being a blood donor (or having donated blood) from 8 weeks before the start of the study and during the study - Not or difficult to venipuncture as evidenced during the screening visit |
Country | Name | City | State |
---|---|---|---|
Netherlands | University Medical Center Groningen | Groningen |
Lead Sponsor | Collaborator |
---|---|
University Medical Center Groningen | Nedmag Industries Mining and Manufacturing B.V. |
Netherlands,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in vascular stiffness | Measured from carotid-femoral pulse wave velocity (PWV). For this assessment, a SphygmoCor will be used (SphygmoCor v9, AtCor Medical). | Baseline, FU-1 (2 weeks), FU-2 (12 weeks), and FU-3 (24 weeks) | |
Secondary | Change in blood pressure | Measured from a semi continuous blood pressure monitoring device | Baseline, FU-1 (2 weeks), FU-2 (12 weeks), and FU-3 (24 weeks) | |
Secondary | Change in gut microbiota | Measured from fecal samples | Baseline, FU-1 (2 weeks), FU-2 (12 weeks), and FU-3 (24 weeks) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03255187 -
Effect of Dietary Supplemental Fish Oil in Alleviating Health Hazards Associated With Air Pollution
|
N/A | |
Completed |
NCT05997303 -
Continuous Norepinephrine Administration and Blood Pressure Stability During Anesthetic Induction
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT03918486 -
Caretaker vs. Routine Blood Pressure Sphygmomanometer
|
||
Completed |
NCT03410342 -
The Effects of Types of Fruits and Vegetables on Vascular Function
|
N/A | |
Active, not recruiting |
NCT05062161 -
Sleep Duration and Blood Pressure During Sleep
|
N/A | |
Not yet recruiting |
NCT04087070 -
Blood Pressure Estimation Using Noninvasive Biosignals During Pediatric Anesthesia
|
||
Completed |
NCT03294928 -
Arterial Waveform Analysis Applying Different Positive End-Expiratory Pressure (PEEP) Levels in Healthy Volunteers
|
N/A | |
Completed |
NCT03859934 -
Metabolic Effects of Melatonin Treatment
|
Phase 1 | |
Completed |
NCT03997461 -
Comparison of Arterial Tonometry Sensor With Standard Oscillometric Blood Pressure Monitoring Device
|
N/A | |
Completed |
NCT03290716 -
Diet, ExerCIse and carDiovascular hEalth (DECIDE) - Salt Reduction Strategies for the Elderly in Nursing Homes in China
|
N/A | |
Recruiting |
NCT06460233 -
Blood Pressure Changes After Bariatric Surgery
|
||
Recruiting |
NCT05196048 -
Blood Pressure Sensor of Watch-type Device With ECG Technology
|
||
Terminated |
NCT03325933 -
Resistance Training and Cardiometabolic Health
|
N/A | |
Not yet recruiting |
NCT06405880 -
Pharmacist Case Finding and Intervention for Vascular Prevention Trial
|
N/A | |
Completed |
NCT02924454 -
Effects of Lipid Emulsion on the Pharmacokinetic and Pharmacodynamic Properties of Metoprolol.
|
Phase 4 | |
Completed |
NCT02451059 -
Reducing Socioeconomic Disparities in Health at Pediatric Visits
|
N/A | |
Active, not recruiting |
NCT02670967 -
Effects of Soluble Fiber on Blood Pressure: A Meta-analysis of Randomly-controlled Trials
|
N/A | |
Completed |
NCT02239744 -
Intervention Study on the Health Impact of Air Filters in Chinese Adults
|
N/A | |
Completed |
NCT02271633 -
Nitrate Supplementation; Source
|
Phase 4 |